A Study of Real-World Outcomes of Ribociclib in First-Line Treatment for Metastatic HR+/HER2- Breast Cancer
Clinical trial NCT07086196 · COMPLETED
Trial details
- NCT number
- NCT07086196
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2024-05-30
- Primary completion
- 2024-08-30
- Enrollment
- 350
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.